Compugen Ltd. Stock
Compugen Ltd. Stock
There is an upward development for Compugen Ltd. compared to yesterday, with an increase of €0.040 (2.050%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Compugen Ltd. stock is not clear.
Based on the current price of 1.99 € the target price of 5 € shows a potential of 151.26% for Compugen Ltd. which would more than double the current price.
Pros and Cons of Compugen Ltd. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Compugen Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Compugen Ltd. | 2.050% | -3.398% | 5.851% | 51.216% | 51.216% | 113.978% | -63.486% |
| Intellia Therapeutics Inc | 2.650% | -3.176% | -35.096% | -12.783% | 21.061% | -75.403% | -91.797% |
| Chromadex Corp | -0.720% | -4.730% | -1.399% | -65.818% | -48.727% | 88.000% | -62.895% |
| Polynovo Ltd | -5.220% | -6.916% | -6.916% | -26.222% | -26.765% | -46.738% | -65.175% |
Comments
Compugen (CGEN) is now covered by Lake Street Capital. They set a "buy" rating and a $6.00 price target on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $4.00 price target on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for CGEN provided by MarketBeat
News
Compugen Q1 Earnings Call Highlights
Key Points
- Interested in Compugen Ltd.? Here are five stocks we like better.
- COM701 ovarian trial is on schedule: Compugen said all sites are open and enrolling in its MAIA-ovarian study, and
